CD8A and neoplasm: Another study from Thirukkumaran et al. showed that the combination treatment with RV and bortezomib leads to significant immune modulation, increasing CD8+ and CD4+ tumor infiltrating lymphocytes (TILs), activated NK-T cells while reducing Tregs and TAMs, thus reversing myeloma-induced immune suppression [99].